HDLM-2

HDLM-2

Cat.No.: CSC-C0201

Species: Homo sapiens (Human)

Source: Pleural Effusion

Morphology: single, round to polygonal cells in suspension; heterogeneity in cell size, 15-100 μm or larger; many bi- and polynucleated cells

Culture Properties: suspension

  • Specification
  • Background
  • Scientific Data
  • Q & A
  • Customer Review
  • Documents
Cat.No.
CSC-C0201
Description
Established from the pleural effusion of a 74-year-old man with Hodgkin lymphoma (nodular sclerosing, stage IV) in 1982
Species
Homo sapiens (Human)
Source
Pleural Effusion
Recommended Medium
Culture Properties
suspension
Morphology
single, round to polygonal cells in suspension; heterogeneity in cell size, 15-100 μm or larger; many bi- and polynucleated cells
STR DNA Profile
Amelogenin: X,Y D19S433: 12,15 D5S818: 11 D21S11: 29 D18S51: 14 D6S1043: 11,12 D3S1358: 14,15 D13S317: 11,12 D7S820: 8,10 D16S539: 12 CSF1PO: 11,12 Penta D: 13,14 D2S441: 11 vWA: 19 D8S1179: 13,14 TPOX: 8 Penta E: 12 TH01: 6, 7 D12S391: 15, 23 D2S1338: 17 FGA: 21,23
Karyotype
Remarkable human hypodiploid cell line with large number of rearrangements involving all chromosomes except ch 10 - 36(35-38)<2n>X, der(Y), breakpoints at: 1p21, 1q11, 2p14, 2q37, 3q21, 3p14, 3q11, 3q25.2, 3q27, 4q25, 5q11, 5q35, 6q15/16, 7p14, 8q21.1, 8q
Markers
CD2 +, CD3 -, CD4 (+), CD13 -, CD14 -, CD15 +, CD19 -, CD21 -, CD25 +, CD30 +, HLA-DR +
Sequence Variations
TP53 p.Ser261fs c.?(782delins)
Application
a. Hodgkin lymphoma related reserach
b. Cell-Based assay
c. In vivo efficacy study
Disease
Hodgkin Lymphoma
Quality Control
Mycoplasma: Fluorescence (DAPI) test: negative; Mycoplasma specific PCR: negative; Selective biochemical test: negative
Viruses: ELISA: reverse transcriptase negative; PCR: EBV +, HBV -, HCV -, HHV-8 -, HIV-1 -, HIV-2 -, HTLV-I/II -, MLV -, SMRV -
Storage and Shipping
Ship in dry ice.
Store in liquid nitrogen.
BioSafety Level
BSL–1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.,
Synonyms
HD-LM-2; HDLM2
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

The HDLM-2 cell line is a widely used and well-characterized cell line that was established from the pleural effusion of a 74-year-old man diagnosed with Hodgkin lymphoma (HL, nodular sclerosing subtype, stage IV) in 1982. The HDLM-2 cell line represents a specific subtype of HL known as nodular sclerosing, which is one of the most common subtypes of the disease. Nodular sclerosing HL is characterized by the presence of large, tumor-like masses called nodules within the lymph nodes, along with fibrosis or scarring in the surrounding tissues.

The establishment of the HDLM-2 cell line has provided researchers with a valuable tool for studying the biology, pathogenesis, and therapeutic responses of HL. The cell line has been extensively studied and characterized, allowing for in vitro and in vivo investigations of various aspects of the disease. Researchers have used HDLM-2 cells to explore the genetic and molecular alterations present in HL, the signaling pathways involved in its development and progression, and the mechanisms of resistance to treatment.

Development of an exon 27-skipping antisense oligonucleotide as a targeted therapy for refractory skin ulcers in Werner syndrome

Molecular Therapy Nucleic Acids | DOI | Paper |

Background

This study develops WRN-108, a splice-switching antisense oligonucleotide that induces exon 27 skipping to correct the frameshift caused by the common WRN c.3139-1G>C mutation in Werner syndrome. In patient fibroblasts, WRN-108 restored WRN protein expression and nuclear localization, improved proliferation, and reduced senescence, G-quadruplex accumulation, and γH2AX signaling. Topical WRN-108 penetrated rat and monkey skin wounds, produced exon 27-skipped transcripts in vivo, and showed favorable tolerability, supporting localized ASO therapy for refractory Werner syndrome skin ulcers.

Key Findings

WRN-108, a 2′-MOE phosphorothioate ASO, induced exon 27 skipping with an EC50 of 2.6 nM in Werner syndrome fibroblasts, restoring WRN protein expression and nuclear localization. It reduced G-quadruplex accumulation and γH2AX DNA damage signaling, increased proliferation up to 5.3-fold, and lowered senescence markers CD44, IL-6, IL-8, and CDKN1A. Topical WRN-108 penetrated rat wounds, achieving sustained dermal concentrations for 7 days with minimal plasma exposure and low organ levels. In cynomolgus monkey skin wounds, WRN-108 produced exon 27-skipped transcripts and high local concentrations without local toxicity. Mice and miniature pig toxicity studies showed tolerability, supporting ASO-mediated exon skipping for refractory Werner syndrome skin ulcers with the c.3139-1G>C mutation.

Contribution

Creative Bioarray provided the HDLM-2 human Hodgkin lymphoma cell line (Cat. no. CSC-C0201), used to assess potential off-target effects of WRN-108. These cells expressed predicted off-target genes, enabling validation that WRN-108 did not alter HHLA2, GRHL2, or DPP10 expression.

WRN-108-induced exon 27 skipping restores WRN protein expression and nuclear localization in WS fibroblasts
Fig. 1. WRN-108-induced exon 27 skipping restores WRN protein expression and nuclear localization in WS fibroblasts

FBXL20-mediated ubiquitination triggers the proteasomal degradation of 4-1BB

The FEBS Journal | DOI | Paper |

Background

4-1BB (TNFRSF9/CD137) is an inducible immune costimulatory receptor, but its protein-level regulation remained unclear. This study shows that mature, heavily N-glycosylated 4-1BB is polyubiquitinated on intracellular lysines and degraded by the ubiquitin-proteasome system. Using BioID proximity labeling, the authors identify FBXL20 as an E3 ligase that interacts with 4-1BB, promotes its polyubiquitination, and reduces its abundance. FBXL20 knockdown stabilizes 4-1BB, while high FBXL20 correlates with poor cancer survival and immunotherapy outcomes. The work reveals a posttranslational mechanism controlling 4-1BB homeostasis and suggests FBXL20 as a potential target for 4-1BB-directed therapy.

Key Findings

4-1BB is polyubiquitinated on intracellular lysines K214, K218, K219, and K225; mutation of these residues (4KR) reduces ubiquitination, increases 4-1BB stability, elevates membrane expression, and enhances NF-κB signaling. The heavily N-glycosylated, post-Golgi mature form is preferentially degraded by the ubiquitin-proteasome system, as proteasome inhibition with MG-132 rapidly increases endogenous 4-1BB protein without affecting mRNA. BioID proximity-labeling proteomics identified FBXL20 as the E3 ligase interacting with 4-1BB. FBXL20 overexpression increases 4-1BB polyubiquitination and decreases its protein level, whereas FBXL20 knockdown or an F-box-deleted FBXL20 mutant blocks ubiquitination and causes 4-1BB accumulation. Clinically, high FBXL20 expression correlates with worse overall survival in KIRP and ovarian cancer and poorer immune checkpoint therapy outcomes. Together, these findings define FBXL20-mediated ubiquitination as a key posttranslational regulator of 4-1BB abundance and a potential therapeutic target.

Contribution

Creative Bioarray supplied the HDLM-2 Hodgkin's lymphoma cell line used in this study. HDLM-2 cells were cultured and treated with MG-132 to demonstrate proteasome inhibition increases endogenous 4-1BB protein without increasing mRNA, supporting posttranslational ubiquitin-proteasome-mediated degradation. This validated cell model enabled key biochemical analysis of endogenous 4-1BB turnover.

FBXL20 promotes the polyubiquitination and degradation of 4-1BB.
Fig. 2. FBXL20 promotes the polyubiquitination and degradation of 4-1BB.

Effect of ECP on Hodgkin Lymphoma Cell Lines

In HL, tumor eosinophilia indicates poor prognosis, probably caused by eosinophil-induced stimulation of tumor cells. The study was to investigate the effects of eosinophil cationic protein (ECP) on HL tumor cells in vitro. All cell lines were sensitive to ECP but to various degrees. At low concentrations of ECP, HDLM-2 was more sensitive than the L428 and particularly the KMH2 cell lines (Fig. 1). At higher concentrations the opposite was seen, with a more pronounced reduction in SI for L428 and KMH2 as compared to HDLM-2, where a plateau effect was seen.

For HDLM-2 (Fig. 1), a reduction in SI was evident at the lowest ECP concentration tested, 0.004 μM (p < 0.01). At a concentration of 0.018 μM, a plateau in SI of about 70% was reached. No statistically significant difference was determined from the concentration of 0.018 μM ECP and the higher ECP concentrations (ECP up to 1.14 μM) added, thus showing a true plateau.

In an additional experiment, HDLM-2 cells were incubated with or without ECP (LMW-ECP II at 0.07 μM) for 72 hours, after which a new serum-containing medium without ECP was added. Figure 2 shows HDLM-2 cells first after 72 hours of incubation with ECP, and then after an additional 72 hours of culture with serum. The cells continued to grow exponentially after the serum was added; this indicated that ECP caused no injury to the surviving HDLM-2 cells that affected their proliferation.

Fig. 1 The cytotoxic effect of LMW-ECP II on the cell lines HDLM-2 (filled circles), L428 (white squares), and KMH2 (filled triangles). (Glimelius I, et al., 2011)Fig. 3. The cytotoxic effect of LMW-ECP II on the cell lines HDLM-2 (filled circles), L428 (white squares), and KMH2 (filled triangles). (Glimelius I, et al., 2011)

Fig. 2 HDLM-2 cells cultured in 24-well plates with LMW-ECP II at a concentration of 0.07 μM for 72 hours. (Glimelius I, et al., 2011)Fig. 4. HDLM-2 cells cultured in 24-well plates with LMW-ECP II at a concentration of 0.07 μM for 72 hours. (Glimelius I, et al., 2011)

Ask a Question

Write your own review

  • You May Also Need

For research use only. Not for any other purpose.

Hot Products